The Competition and Markets Authority (CMA) has issued fines as a result of their nortriptyline investigation. Nortriptyline is an unbranded, prescription-only generic medicine used for the relief of symptoms of depression. In some cases, it can be used to treat neuropathic pain and nocturnal enuresis (bed-wetting).
The CMA has recently issued decisions imposing fines on suppliers of nortriptyline tablets for reportedly breaching competition law after their nortriptyline investigation concluded. There have also been director disqualifications.
The Competition and Markets Authority (CMA) has launched an investigation into the supply of lithium-based medication, used to treat bipolar disorder.
The CMA has announced the investigation will look into prominent pharmaceutical company, Essential Pharma. They are suspected to have abused an alleged dominant position as a medication supplier by proposing to withdraw the supply of lithium-based medication to UK patients.
The privately funded healthcare competition investigation was initiated by the CMA (Competition and Markets Authority) last month.
At this stage, it’s only an initial investigation, and as the CMA often confirm, there are no assumptions to be made at this moment in time. What we do know is that a decision as to whether the investigation will continue or not is set to be made in the next couple of months.
As more and more services are outsourced to the private sector in relation to healthcare, this could be a significant investigation.